Cargando…

CAXII Is a Surrogate Marker for Luminal Breast Tumors Regulated by ER and GATA3

SIMPLE SUMMARY: Breast cancer is a heterogeneous disease and treatment needs to be adapted to individual tumors. Two thirds of breast tumors may benefit from treatment with drugs targeting a specific protein, the estrogen receptor alpha, a regulator of gene expression activated by female sex hormone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Porras, Lucas, Gorse, Faustine, Thiombane, Ndeye Khady, Gaboury, Louis, Mader, Sylvie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657334/ https://www.ncbi.nlm.nih.gov/pubmed/36358871 http://dx.doi.org/10.3390/cancers14215453

Ejemplares similares

CAXII Is a Sero-Diagnostic Marker for Lung Cancer
por: Kobayashi, Makoto, et al.
Publicado: (2012)

Tiliroside suppresses triple-negative breast cancer as a multifunctional CAXII inhibitor
por: Han, Rui, et al.
Publicado: (2022)

Expression of transmembrane carbonic anhydrases, CAIX and CAXII, in human development
por: Liao, Shu-Yuan, et al.
Publicado: (2009)

CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
por: Han, Rui, et al.
Publicado: (2023)

Differential expression and function of CAIX and CAXII in breast cancer: A comparison between tumorgraft models and cells
por: Chen, Zhijuan, et al.
Publicado: (2018)

Inhibition of Melanoma Cell Migration and Invasion Targeting the Hypoxic Tumor Associated CAXII
por: Giuntini, Gaia, et al.
Publicado: (2020)

Role of the Hedgehog Pathway and CAXII in Controlling Melanoma Cell Migration and Invasion in Hypoxia
por: Giuntini, Gaia, et al.
Publicado: (2022)

Cathepsin V suppresses GATA3 protein expression in luminal A breast cancer
por: Sereesongsaeng, Naphannop, et al.
Publicado: (2020)

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes
por: Maisonneuve, Patrick, et al.
Publicado: (2014)

Positive Regulation of Estrogen Receptor Alpha in Breast Tumorigenesis
por: Porras, Lucas, et al.
Publicado: (2021)

GATA3 frameshift mutation promotes tumor growth in human luminal breast cancer cells and induces transcriptional changes seen in primary GATA3 mutant breast cancers
por: Gustin, John P., et al.
Publicado: (2017)

Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis
por: Han, Rui, et al.
Publicado: (2021)

A simple and reproducible prognostic index in luminal ER-positive breast cancers
por: Castellano, I., et al.
Publicado: (2013)

TOX3 is expressed in mammary ER(+) epithelial cells and regulates ER target genes in luminal breast cancer
por: Seksenyan, Akop, et al.
Publicado: (2015)

Breast cancer in Iraq is associated with a unimodally distributed predominance of luminal type B over luminal type A surrogates from young to old age
por: Majid, Runnak A, et al.
Publicado: (2017)

High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers
por: Voutsadakis, Ioannis A.
Publicado: (2022)

Studying the Genomic Role of Cathepsin-D in ER(+) Breast Cancer
por: Dianati, Elham, et al.
Publicado: (2021)

Calcium sensing by the STIM1 ER-luminal domain
por: Gudlur, Aparna, et al.
Publicado: (2018)

Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer
por: Jacquemier, Jocelyne, et al.
Publicado: (2009)

ER-luminal [Ca(2+)] regulation of InsP(3) receptor gating mediated by an ER-luminal peripheral Ca(2+)-binding protein
por: Vais, Horia, et al.
Publicado: (2020)

A mouse model for Luminal epithelial like ER positive subtype of human breast cancer
por: Kumar, MJ Mahesh, et al.
Publicado: (2007)

ERβ alters the chemosensitivity of luminal breast cancer cells by regulating p53 function
por: Bado, Igor, et al.
Publicado: (2018)

GATA3 Truncation Mutants Alter EMT Related Gene Expression via Partial Motif Recognition in Luminal Breast Cancer Cells
por: Saotome, Mika, et al.
Publicado: (2022)

OR11-02 Structural Determinants of Pure Antiestrogenic Activity
por: Vallet, Amandine, et al.
Publicado: (2023)

LSD1 suppresses invasion, migration and metastasis of luminal breast cancer cells via activation of GATA3 and repression of TRIM37 expression
por: Hu, Xin, et al.
Publicado: (2019)

The therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtype
por: Bertucci, François, et al.
Publicado: (2020)

Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers
por: Sung, Hyuna, et al.
Publicado: (2016)

TRPS1 modulates chromatin accessibility to regulate estrogen receptor (ER) binding and ER target gene expression in luminal breast cancer cells
por: Scott, Thomas G., et al.
Publicado: (2023)

Self-Association of Purified Reconstituted ER Luminal Spacer Climp63
por: Zhao, Jinghua, et al.
Publicado: (2020)

Surrogate Adiposity Markers and Mortality
por: Khan, Irfan, et al.
Publicado: (2023)

Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes
por: Teinturier, Romain, et al.
Publicado: (2021)

Breast Arterial Calcification: A Potential Surrogate Marker for Cardiovascular Disease
por: Suh, Jung-Won, et al.
Publicado: (2018)

Elastosis in Breast Cancer as a Surrogate Marker for Estrogen Receptor Positivity
por: Al Abri, Samah, et al.
Publicado: (2021)

Prognostic Value of Lymphangiogenesis Determinants in Luminal and Non-luminal Breast Carcinomas
por: Widodo, Irianiwati, et al.
Publicado: (2018)

CCPG1 recognizes endoplasmic reticulum luminal proteins for selective ER-phagy
por: Ishii, Shunsuke, et al.
Publicado: (2023)

RUNX1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells
por: van Bragt, Maaike PA, et al.
Publicado: (2014)

Luminal lncRNAs Regulation by ERα-Controlled Enhancers in a Ligand-Independent Manner in Breast Cancer Cells
por: Miano, Valentina, et al.
Publicado: (2018)

Surrogate markers in antiangiogenesis clinical trials
por: Davis, D W, et al.
Publicado: (2003)

Insulin Resistance: Quest for Surrogate Markers
por: Mahajan, Rajiv
Publicado: (2017)

Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells
por: Traboulsi, Tatiana, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8b7lunpm2ejnfnvah8oiac4ka3